(E)-5-乙酰氧基-2-氨基-3,4,14-三羟基二十碳-6-烯酸 | 121025-46-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: (E)-5-乙酰氧基-2-氨基-3,4,14-三羟基二十碳-6-烯酸
• 英文名称: eicosenoic acid
• 英文别名: sphingofungin C；(E,2S,3R,4S,5S,14R)-5-acetyloxy-2-amino-3,4,14-trihydroxyicos-6-enoic acid
• CAS: 121025-46-5
• 化学式: C₂₂H₄₁NO₇
• 分子量: 431.57
• InChiKey: PBKBHDLANIOIKK-RXCFHPIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  30
• 可旋转键数：
  19
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  150
• 氢给体数：
  5
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (E)-5-乙酰氧基-2-氨基-3,4,14-三羟基二十碳-6-烯酸 在 甲醇 、 三乙胺 作用下， 以38%的产率得到sphingofungin D
  参考文献：
  名称：

  抗真菌鞘氨醇家族的模块化方法：鞘氨醇 A 和 C 的简明全合成

  摘要：

  通过结合多功能脱羧偶联反应和交叉复分解方案，开发了抗真菌和抗寄生虫鞘氨醇 A-D 及其同系物的简短而灵活的全合成。

  DOI：

  10.1002/anie.202112616
• 作为产物：
  描述：

  tert-butyl (2S)-2-[(4R,5R)-5-[(1S)-1-acetyloxyprop-2-enyl]-2,2-dimethyl-1,3-dioxolan-4-yl]-2-[[(S)-(2,4,6-trimethylphenyl)sulfinyl]amino]acetate 在 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 、 copper(l) iodide 、 三氯化硼 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 (E)-5-乙酰氧基-2-氨基-3,4,14-三羟基二十碳-6-烯酸
  参考文献：
  名称：

  抗真菌鞘氨醇家族的模块化方法：鞘氨醇 A 和 C 的简明全合成

  摘要：

  通过结合多功能脱羧偶联反应和交叉复分解方案，开发了抗真菌和抗寄生虫鞘氨醇 A-D 及其同系物的简短而灵活的全合成。

  DOI：

  10.1002/anie.202112616

文献信息

• USE OF A SERINE PALMITOYLTRANSFERASE (SPT) INHIBITOR TO TREAT ATHEROSCLEROSIS AND DYSLIPIDEMIA
  申请人：Warner-Lambert Company LLC

  公开号：EP1732538A1

  公开（公告）日：2006-12-20
• ANTI-VIRAL COMBINATION THERAPY
  申请人：THE TRUSTEES OF PRINCETON UNIVERSITY

  公开号：EP2725902A2

  公开（公告）日：2014-05-07
• Imidazole-Based Hmg-Coa Reductase Inhibitors
  申请人：Homan Reynold

  公开号：US20080027088A1

  公开（公告）日：2008-01-31

  The present invention relates to methods of treating atherosclerosis, dyslipidemia, other cardiovascular diseases and related diseases, such as diabetes, using a serine palmitoyltransferase (SPT) inhibitor. The present invention also relates to pharmaceutical compositions and kits that comprise a serine palmitoyltransferase (SPT) inhibitor, optionally with another pharmaceutical agent.
• Compositions and methods for treatment of viral diseases
  申请人：Johansen Lisa M.

  公开号：US20100092479A1

  公开（公告）日：2010-04-15

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E).
• [EN] DETECTION AND TREATMENT OF ATHEROSCLEROSIS BASED ON PLASMA SPHINGOMYELIN CONCENTRATION<br/>[FR] DETECTION ET TRAITEMENT DE L'ATHEROSCLEROSE BASES SUR LA CONCENTRATION DE SPHINGOMYELINE DANS LE PLASMA
  申请人：UNIV COLUMBIA

  公开号：WO2001080903A1

  公开（公告）日：2001-11-01

  Disclosed are new enzymatic methods of plasma and tissue sphingomyelin concentration measurement. Also disclosed is that human plasma sphingomyelin levels are strongly positively correlated with atherosclerosis and coronary heart disease. Thus, the use of a quick and effective plasma sphingomyelin measurement such as the subject invention, is valuable for screening assays in vitro, in cell culture or in animals to develop drugs or other treatments aimed to lower plasma sphingomyelin levels. The findings indicate that therapies aimed at reducing plasma or tissue SM levels are likely to have therapeutic benefit. These would include inhibition of sphingomyelin synthesis in the liver or arterial wall, as well as methods to enhance clearance of sphingomyelin from plasma. Thus, compounds which inhibit sphingomyelin biosynthesis or induce sphingomyelin clearance are also disclosed.